Sample calculations based on data in tables 3 and 4
| Case type | Annual risk of TB disease/100 000 | TB risk adjusted ×5 for anti-TNF effect | Risks of prophylaxis /100 000 (table 6) | Risk/benefit conclusion |
|---|---|---|---|---|
| The weighted average risk for prophylaxis with isoniazid (6H) is 278/100 000 which is used for these calculations. The weighted average risk for rifampicin/isoniazid (3RH is higher at 1766/100 000, but this regimen may need to be considered if a shorter duration of chemoprophylaxis is needed on clinical grounds (see section 4.6). | ||||
| White | 7 | 35 | 278 | Observation |
| Age 55–74 | ||||
| UK born | ||||
| ISC | 593 | 2965 | 278 | Prophylaxis |
| Age >35 | ||||
| In UK 3 years | ||||
| Black African | 168 | 840 | 278 | Prophylaxis |
| Age 35–54 | ||||
| Other ethnic | 39 | 195 | 278 | Observation |
| Age 35+ | ||||
| In UK >5 years | ||||